[{"orgOrder":0,"company":"Epitopea","sponsor":"Innovate UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cryptigen-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epitopea \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Epitopea \/ Innovate UK"},{"orgOrder":0,"company":"Epitopea","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epitopea \/ Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Universit\u00e9 de Montr\u00e9al"},{"orgOrder":0,"company":"Epitopea","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Epitopea \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Epitopea","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epitopea \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Merck & Co"},{"orgOrder":0,"company":"Epitopea","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epitopea \/ Epitopea","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Epitopea"}]